Physician
Shah Khan, Sardar
Shah Khan, Sardar was paid $483K by Medicaid between Jan 2018 and Dec 2024, across 8 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 49% of everything it billed.
33Billing provider infoSHAH KHAN, SARDAR
MORGANTON, NC 28655
MORGANTON, NC 28655
33aNPI1366401036assigned 03/21/2006
33bProvider typeCardiovascular Disease Physician
28Total paid$483K
24GClaims9,424
24DCodes billed8
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiovascular Disease Physician providers in North Carolina
Rank by total paid#17 of 109
Median peer was paid$58K
This provider vs. median8.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,440 | $60K | |
| 2019 | 1,365 | $89K | |
| 2020 | 1,000 | $86K | |
| 2021 | 957 | $76K | |
| 2022 | 1,364 | $74K | |
| 2023 | 1,642 | $53K | |
| 2024incomplete | 1,656 | $44K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 49% | 4,737 | 3,551 | $235K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 48% | 2,303 | 1,683 | $230K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 124 | 113 | $7K |
| 80305 | 1.2% | 1,036 | 825 | $6K | |
| 99199 | Unlisted special service, procedure or report | <1% | 1,009 | 1,009 | $4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 76 | 71 | $1K |
| 82962 | <1% | 117 | 78 | $156.06 | |
| 81002 | <1% | 22 | 22 | $3.15 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.